ASH 2018 | Tagraxofusp for BPDCN gives encouraging results
Naveen Pemmaraju
With no approved treatment options for blastic plasmacytoid dendritic cell neoplasm (BPDCN), Naveen Pemmaraju, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, presents the results of a Phase II study (NCT02113982) testing the novel agent SL-401 (tagraxofusp). Speaking at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA., Dr Pemmaraju discusses the breakthrough finding that CD123 is overexpressed in all these patients, and how use of the first-in-class tagraxofusp has shown high response rates in this patient population.
Related videos
An exciting era for CAR T-cell therapy
Mohamad Mohty
6:39
Molecular techniques for monitoring MRD in AML
Torsten Haferlach
2:33
NGS: a valuable tool for elucidating the genetic landscape of AML
Torsten Haferlach
1:59
Understanding the biology behind AML relapse
Charles Craddock
3:25
FLT3 inhibitors as a strategy to treat AML
Charles Craddock
